New Inhibitors of β-1,4-Galactosyltransferase I Discovered by Virtual Screening

Area of Science:

• Biochemistry
• Enzymology
• Drug Discovery

Background:

• Beta-1,4-galactosyltransferase I (beta-1,4-GALT1) is a key enzyme in cellular galactosylation.
• Galactosylation abnormalities are linked to various pathophysiological conditions.
• Existing beta-1,4-GALT1 inhibitors often have poor cell permeability and limited in vivo efficacy.

Purpose of the Study:

• To identify novel beta-1,4-GALT1 inhibitors with improved properties.
• To explore new chemotypes for targeting beta-1,4-GALT1.
• To advance drug discovery for galactosylation-related diseases.

Main Methods:

• In silico screening of commercially available virtual compound libraries.
• Molecular docking of compounds to the beta-1,4-GALT1 binding site.
• Biological evaluation of selected compounds for inhibitory activity and determination of IC50 values.

Main Results:

• Discovery of novel beta-1,4-GALT1 inhibitors through virtual screening.
• Identification of new chemotypes with potential for enhanced cell permeability.
• Quantification of inhibitory activity for the most effective compounds.

Conclusions:

• In silico screening is an effective strategy for discovering novel beta-1,4-GALT1 inhibitors.
• The identified compounds represent promising starting points for developing new therapeutics.
• Further development could lead to improved treatments for diseases associated with galactosylation defects.